Abstract：
UNASSIGNED: This study aimed to investigate the association of hormone replacement therapy (HRT) use, type, duration and age of commencement with myocardial infarction (MI) and stroke in postmenopausal Korean women.
UNASSIGNED: This nested case-control study used data from the National Health Insurance Service database to analyze 2017 data from women aged ≥50 years and diagnosed with natural menopause between 2004 and 2007. Among 356,160 eligible women, 36,446 used HRT for ≥1 year and 319,714 did not (controls). These two groups were matched 1:1 for statistical analysis. Type and duration were categorized into three categories.
UNASSIGNED: Women who started estrogen-progestogen therapy (EPT) or estrogen therapy (ET) in their 50s, or EPT or tibolone in their ≥60s exhibited a lower stroke risk than controls. MI risk was lower among women who used tibolone - regardless of duration - or EPT or ET for 1-3 years than among controls. Stroke risk was lower with tibolone use for ≥5 years or with EPT or ET use for 1-3 years or ≥5 years than non-users.
UNASSIGNED: Our study may support the beneficial effect of HRT by showing that Korean postmenopausal women who used HRT at a relatively younger and healthier age had a relative benefit for MI and stroke.
UNASSIGNED: This nested case-control study used data from the National Health Insurance Service database to analyze 2017 data from women aged ≥50 years and diagnosed with natural menopause between 2004 and 2007. Among 356,160 eligible women, 36,446 used HRT for ≥1 year and 319,714 did not (controls). These two groups were matched 1:1 for statistical analysis. Type and duration were categorized into three categories.
UNASSIGNED: Women who started estrogen-progestogen therapy (EPT) or estrogen therapy (ET) in their 50s, or EPT or tibolone in their ≥60s exhibited a lower stroke risk than controls. MI risk was lower among women who used tibolone - regardless of duration - or EPT or ET for 1-3 years than among controls. Stroke risk was lower with tibolone use for ≥5 years or with EPT or ET use for 1-3 years or ≥5 years than non-users.
UNASSIGNED: Our study may support the beneficial effect of HRT by showing that Korean postmenopausal women who used HRT at a relatively younger and healthier age had a relative benefit for MI and stroke.
摘要：
■本研究旨在调查使用激素替代疗法（HRT）的关联，type,绝经后韩国女性心肌梗死(MI)和卒中的发病时间和发病年龄.
■这项嵌套病例对照研究使用了国家健康保险服务数据库中的数据，以分析2004年至2007年间年龄≥50岁并被诊断为自然更年期的女性的2017年数据。在356,160名符合条件的妇女中，36,446人使用HRT≥1年，319,714人没有使用(对照)。两组以1:1进行统计学分析。类型和持续时间分为三类。
■50多岁开始雌激素-孕激素治疗（EPT）或雌激素治疗（ET）的女性，≥60岁的EPT或替勃龙的卒中风险低于对照组。与对照组相比，使用替勃龙-无论持续时间如何-或EPT或ET1-3年的女性的MI风险较低。使用替勃龙≥5年或使用EPT或ET1-3年或≥5年的卒中风险低于非使用者。
■我们的研究可能支持HRT的有益效果，因为我们的研究表明，在相对较年轻和健康的年龄使用HRT的韩国绝经后妇女对MI和中风有相对益处。
■这项嵌套病例对照研究使用了国家健康保险服务数据库中的数据，以分析2004年至2007年间年龄≥50岁并被诊断为自然更年期的女性的2017年数据。在356,160名符合条件的妇女中，36,446人使用HRT≥1年，319,714人没有使用(对照)。两组以1:1进行统计学分析。类型和持续时间分为三类。
■50多岁开始雌激素-孕激素治疗（EPT）或雌激素治疗（ET）的女性，≥60岁的EPT或替勃龙的卒中风险低于对照组。与对照组相比，使用替勃龙-无论持续时间如何-或EPT或ET1-3年的女性的MI风险较低。使用替勃龙≥5年或使用EPT或ET1-3年或≥5年的卒中风险低于非使用者。
■我们的研究可能支持HRT的有益效果，因为我们的研究表明，在相对较年轻和健康的年龄使用HRT的韩国绝经后妇女对MI和中风有相对益处。
